Evommune, Inc. (EVMN) — IPO Analysis
By Kian O Connor | Updated 4/29/2026
Company Overview
Performance Overview
Since going public at $16.00 per share on Nov 6, 2025, Evommune, Inc. shares have gained 59.9%, rewarding investors who participated in the IPO. The stock currently trades at $25.58, giving the company a market capitalization of $921.3M.
Lockup Expiration
The lockup period for Evommune, Inc. insiders is set to expire on May 5, 2026, which is 6 days from now. When the lockup expires, insiders and early investors who received shares before the IPO will be free to sell their holdings on the open market. This can create significant selling pressure and is closely watched by traders and institutional investors alike.
Industry Context
Evommune, Inc. operates in the Biotechnology sector, which has seen varied IPO activity in recent years. The company is headquartered in the United States and is classified under SIC code . Understanding the competitive landscape and sector dynamics is essential for evaluating the long-term prospects of any newly public company in this space. Investors should consider broader market conditions, sector-specific trends, and company fundamentals when assessing EVMN as an investment.
Trading History
Evommune, Inc. is actively trading in the public markets with a current share price of $25.58. The company went public at $16.00 per share, resulting in gains of 59.9% for IPO investors. With a current market capitalization of $921.3M, Evommune, Inc. continues to establish its presence as a publicly traded entity in the Biotechnology.
Important Disclaimer
This analysis of Evommune, Inc. (EVMN) is provided for informational purposes only and should not be construed as investment advice. All data is sourced from SEC EDGAR filings and public market feeds. Past performance is not indicative of future results. Investors should conduct their own due diligence and consult with a qualified financial advisor before making investment decisions. IPOLockup.io is an independent research platform with no financial interest in any of the companies covered.